Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Production and purification of research scale 161Tb using cation-exchange semi-preparative HPLC for radiopharmaceutical applications

Journal Article · · Radiochimica Acta
 [1];  [1];  [1];  [1];  [1];  [1];  [2];  [2];  [3];  [3];  [1];  [1];  [1]
  1. Univ. of Missouri, Columbia, MO (United States)
  2. Brookhaven National Laboratory (BNL), Upton, NY (United States)
  3. Univ. of Washington, Seattle, WA (United States)
+ Show Author Affiliations
Terbium-161 (161Tb) is emerging as a promising radionuclide for cancer therapy due to its favorable nuclear properties that are similar to clinically established lutetium-177 (177Lu) along with its therapeutic edge arising from the higher number of Auger and conversion electrons per decay. These low energy electrons result in higher cytotoxicity within a short range of the decaying nuclei to enhance therapeutic efficacy. Despite these promising characteristics, a significant challenge remains in the lack of a domestic 161Tb supply in the United States, which poses an obstacle to the advancement of 161Tb-based radiopharmaceutical research and development. Here, this study developed a reliable cation-exchange high-performance liquid chromatography-based method for purification of reactor-produced 161Tb at quantities suitable to support research and preclinical studies. The purified 161Tb product showed high radionuclidic purity with excellent radiochemical purity, and the successful labeling studies with the DOTA chelator and DOTA-TATE peptide demonstrated the effective incorporation of the purified 161Tb into radiopharmaceuticals designed for targeted cancer therapy.
Research Organization:
Univ. of Missouri, Columbia, MO (United States)
Sponsoring Organization:
USDOE Office of Science (SC), Office of Isotope R&D and Production (IRP)
Grant/Contract Number:
SC0022235
OSTI ID:
2568814
Journal Information:
Radiochimica Acta, Journal Name: Radiochimica Acta Journal Issue: 6 Vol. 113; ISSN 2193-3405; ISSN 0033-8230
Publisher:
de GruyterCopyright Statement
Country of Publication:
United States
Language:
English

References (17)

Reactor-Produced Therapeutic Radionuclides book January 2016
Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate journal October 2013
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer journal May 2019
Separation and direct detection of heavy lanthanides using new ion-exchange chromatography: fast Fourier transform continuous cyclic voltammetry system journal April 2010
Alternative chromatographic processes for no-carrier added 177Lu radioisotope separation journal April 2008
Separation of radioactive terbium from massive Gd targets for medical use journal February 2018
Radiochemical separation of no-carrier-added as produced via the process journal September 2000
The production and separation of 161Tb with high specific activity at the University of Utah journal December 2024
Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications journal March 2019
The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy journal August 2011
Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice journal May 2014
Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy journal July 2019
Separation of ytterbium from 177Lu/Yb mixture by electrolytic reduction and amalgamation journal July 2014
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine journal September 2019
First-in-Humans Application of 161 Tb: A Feasibility Study Using 161 Tb-DOTATOC journal February 2021
Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug journal July 2022
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617 journal January 2024

Similar Records

The production and separation of 161Tb with high specific activity at the University of Utah
Journal Article · Tue Sep 24 20:00:00 EDT 2024 · Applied Radiation and Isotopes · OSTI ID:2475657
Production of High Specific Activity 155Tb, 161Tb and 203Pb for Research and Clinical Applications: Effective Target Design, Target Material Recycling and Radioisotope Separation (Final Technical Report)
Technical Report · Tue Nov 26 19:00:00 EST 2024 · OSTI ID:2478865
Determination of the 161Tb half-life
Journal Article · Sun Feb 06 19:00:00 EST 2022 · Applied Radiation and Isotopes · OSTI ID:2997703

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
alpha-hydroxyisobutyric acid
cation-exchange resin
high-performance liquid chromatography
lanthanide separation
nuclear medicine
terbium-161